Evaluating the Efficacy of CRISPR-Cas13 Systems in Inhibiting RNA Virus Replication within Human Respiratory Epithelium.
- Apr 19
- 1 min read
Updated: May 7
Original Research | 2026 | Volume 3 | Issue 1 | Page 53- 59
Corresponding Author
Dr. Krishna Chaitanya Paleti, Associate Professor, Department of Biochemistry, Viswabharthi Medical College and General Hospital. Kurnool 518467
Abstract
Introduction: The emergence of novel respiratory RNA viruses continues to pose a significant threat to global health, necessitating the development of programmable, high-precision antiviral therapeutics. While CRISPR-Cas9 has revolutionized DNA editing, the CRISPR-Cas13 system offers a unique advantage by directly targeting and degrading viral RNA. This study evaluates the efficacy of Cas13-mediated interference in inhibiting the replication of diverse RNA viruses within human respiratory epithelial cells.
Methods: Utilizing a primary-like human bronchial epithelial cell line, we engineered a doxycycline-inducible Cas13 expression system. We designed a library of crRNAs targeting highly conserved genomic regions of Influenza A virus (IAV) and SARS-CoV-2. Viral suppression was quantified via quantitative RT-PCR for viral load, plaque assays for infectious progeny, and immunofluorescence for viral protein expression.
Results: Our findings demonstrate that Cas13a and Cas13d variants achieve a 70-95% reduction in viral RNA titers within 24 hours post-infection. Notably, targeting the polymerase genes resulted in the most robust inhibition across multiple viral strains. Furthermore, the system exhibited high specificity with negligible off-target transcriptomic disruptions in the host epithelium, maintaining cell viability and ciliary function.
Conclusion: These results suggest that CRISPR-Cas13 is a potent and flexible tool for neutralizing respiratory RNA viruses. By leveraging the sequence-specific RNase activity of Cas13, this approach provides a promising framework for "prophylactic antiviral" strategies that can be rapidly adapted to combat emerging pathogens, potentially transforming the landscape of respiratory medicine and pandemic preparedness.